MK-677 (Ibutamoren): Risks, Research and Legal Status

MK-677, also called ibutamoren or ibutamoren mesylate, is an orally active non-peptide compound that mimics the hunger hormone ghrelin to stimulate the body’s own growth hormone release. Despite being marketed alongside peptides in fitness circles, it is a small synthetic molecule, chemically closer to a conventional drug than to peptides like sermorelin or ipamorelin.

Ibutamoren was developed by Merck in the 1990s as an oral alternative to injectable growth hormone, under the internal code MK-0677. It has never been approved as a finished medicine, but it carries several names across its different lives: it is sold on the grey market as “Nutrobal,” it is referenced in the research literature as ibutamoren mesylate, and it is now in legitimate clinical development under the name LUM-201. Those three identities, one molecule, capture the strange position MK-677 occupies.

The bottom line: MK-677 is a non-peptide oral ghrelin mimetic, not a peptide, despite how it is marketed.

MK-677 works by binding the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, the same receptor activated by the body’s natural hunger hormone, ghrelin. Activating it triggers a pulse of growth hormone release and suppresses somatostatin, the hormone that normally puts the brakes on growth-hormone secretion. The net effect is a sustained rise in growth hormone and a downstream rise in IGF-1.

Because it copies ghrelin’s full action rather than just one part of it, MK-677 also strongly stimulates appetite, since ghrelin is the primary hunger signal. This is why increased appetite is one of its most consistent and pronounced effects, and why it is a poor fit for anyone trying to lose weight.

Why it works as a daily oral dose

Part of MK-677’s appeal is purely practical. It is one of the few growth-hormone secretagogues that is active by mouth: a small, orally bioavailable molecule with a long half-life of roughly 24 hours, it can hold growth hormone and IGF-1 elevated from a single daily oral dose. The GHRH analogues and growth-hormone-releasing peptides it is usually compared with are peptides that degrade in the gut and so require injection. That oral convenience, rather than any superior result, is the main reason MK-677 has persisted on the grey market despite a thin record of real-world benefit.

Mechanistically, this puts MK-677 in a different group from the GHRH analogues. Tesamorelin, sermorelin and CJC-1295 act on the GHRH receptor, whereas MK-677 and the injectable peptide ipamorelin act on the ghrelin receptor. The big practical difference within that ghrelin-receptor group is selectivity: ipamorelin was designed to trigger growth hormone with little effect on appetite, cortisol or prolactin, while MK-677 produces the broader ghrelin footprint, including the strong appetite drive. That ipamorelin comparison is examined in detail in the section below.

The bottom line: MK-677 activates the ghrelin receptor to raise growth hormone and IGF-1, while also strongly driving appetite.

MK-677 has a paradoxical evidence base: its biomarker effect is one of the most replicable findings in the entire field, while its functional and clinical benefits in adults are weak or absent. Across human trials, 25 mg per day reliably raises IGF-1, from around 40% in obese men (Svensson, 1998) to a sustained rise across twelve months in the Alzheimer’s trial (Sevigny, 2008), to roughly 84% in hip-fracture patients (Bach, 2004). The problem is that this rise does not consistently translate into the strength, function or clinical outcomes that users actually want.

The pivotal ageing trial (Nass, 2008)

The most-cited human study is a two-year randomised controlled trial in healthy older adults by Nass and colleagues, published in the Annals of Internal Medicine in 2008. Daily MK-677 increased fat-free (lean) mass and restored IGF-1 to levels comparable to those of healthy young adults, but it did not improve strength or physical function. Some of the lean-mass gain is attributed to fluid retention rather than new contractile tissue. The trial also documented increased appetite, lower-extremity oedema, muscle pain, raised fasting glucose and reduced insulin sensitivity.

The Alzheimer’s trial that failed (Sevigny, 2008)

Merck tested the IGF-1 hypothesis directly in Alzheimer’s disease. In a randomised controlled trial of 563 patients with mild-to-moderate Alzheimer’s, published in Neurology, MK-677 produced exactly the predicted IGF-1 response (up 73% at twelve months) yet showed no benefit on any cognitive endpoint at any timepoint. The authors concluded the compound was ineffective at slowing the progression of the disease. This is the most direct evidence that raising IGF-1 with MK-677 does not deliver the cognitive benefits sometimes claimed for it.

The hip-fracture trial halted on a safety signal (Adunsky, 2011)

A Phase IIb hip-fracture trial in patients aged 60 and over, reported by Adunsky and colleagues in 2011, did not finish. The independent data monitoring committee halted enrolment early on a safety signal: 4 of 62 patients (6.5%) on MK-677 developed congestive heart failure, compared with 1 of 61 (1.7%) on placebo, alongside rises in blood pressure, glucose and HbA1c. This single finding is the most consequential in the MK-677 safety record and is the reason the FDA flags ibutamoren for congestive-heart-failure risk.

The effect on sleep

One frequently claimed benefit does have trial support: sleep. An early study by Copinschi and colleagues reported that MK-677 increased slow-wave (deep) sleep and REM sleep in both young and older healthy adults, consistent with the growth-hormone axis’s known role in sleep architecture. It is one of the few MK-677 claims backed by controlled human data rather than anecdote. The caveats are real, though: the studies are small and short, the changes were modest, and better sleep does nothing to offset the metabolic and cardiac concerns documented in the longer trials.

The bottom line: Small controlled studies show MK-677 can increase deep and REM sleep, one of the few claimed benefits with trial support.

Why Merck walked away, and what the marketing gets wrong

Merck pursued ibutamoren through the late 1990s and 2000s across several uses, including frailty and functional decline in older people, before abandoning it. The published trials show why: a dependable IGF-1 rise that did not convert into the strength, function or clinical outcomes a marketable drug needs, set against metabolic side effects and, ultimately, the heart-failure signal. That same gap undercuts most of the fitness marketing. MK-677 is sold on promises of muscle growth, fat loss, recovery and anti-ageing, but the trial record supports almost none of it directly: the lean-mass gain in the Nass trial came with no strength benefit and was partly fluid, no human trial shows it causing fat loss (its appetite drive works against that), and the one direct test of a cognition-style outcome failed. The reliable part of its reputation is the biomarker rise; the benefits attributed to that rise are mostly assumed, not shown.

The bottom line: MK-677’s reliable IGF-1 rise has never been shown to deliver the muscle, fat-loss or anti-ageing results it is marketed for.

The legitimate development story most guides miss: LUM-201

While MK-677 is sold as a muscle-building research chemical, the very same molecule is in a genuine Phase 3 trial for a rare children’s disease. Lumos Pharma is developing ibutamoren as LUM-201, a once-daily oral treatment for paediatric growth hormone deficiency, and both the FDA and the European Commission granted it orphan drug designation for growth hormone deficiency in June 2017. Its Phase 2 OraGrowtH210 trial reported an annualised height velocity of around 8 cm per year at the 1.6 mg/kg dose, in line with injectable growth hormone in moderate cases. The programme uses a predictive enrichment marker (PEM) to select children most likely to respond, and the multinational Phase 3 OraGrowtH trial is now under way. Crucially, in children the reported adverse events have been mild (increased appetite, pain in extremity, arthralgia) with no meaningful safety signals to date, a different picture from the elderly hip-fracture population.

Study	Population	Key Finding	Evidence Tier
Nass et al., 2008	Healthy older adults	More lean mass, no gain in strength or function	2-year RCT
Sevigny et al., 2008	563 Alzheimer’s patients	IGF-1 up 73%, no cognitive benefit; trial failed	Phase 3 RCT
Adunsky et al., 2011	Hip-fracture patients 60+	Halted early: congestive heart failure signal	Phase IIb RCT (stopped)
LUM-201 OraGrowtH (Lumos)	Children with GH deficiency	~8 cm/yr height velocity; Phase 3 ongoing	Phase 2 to 3

The bottom line: MK-677 reliably raises IGF-1 but failed in Alzheimer’s, was halted in hip fracture, and showed no strength gain in healthy older adults.

MK-677 is not approved as a medicine in any country and is banned in sport worldwide. In the United States it is an unapproved new drug: the FDA has issued warning letters to companies selling it, has found it hidden in products including one marketed for children, and lists it as posing significant safety risks due to potential congestive heart failure. It is also on the US Department of Defense prohibited supplement list.

A point that often confuses buyers: because MK-677 was never approved as a drug substance, it sits entirely outside the peptide-compounding framework. It is not a bulk substance on the FDA’s 503A or 503B lists and has no Category 1 or Category 2 designation, because those rules apply to compounding approved or eligible substances, which MK-677 is not. How that framework works for actual peptides is explained in our Category 1 vs Category 2 guide.

Jurisdiction	Status	Detail
United States	Unapproved drug	Not approved; FDA warning letters; sold only as research-use-only
United Kingdom	Unlicensed medicine	No marketing authorisation; not legal to sell for human use
Australia	Schedule 4	Prescription-only since 2018; illegal to possess without authority
Sport (WADA)	Prohibited at all times	Listed by name under S2.2.4; no therapeutic use exemption granted

In Australia, ibutamoren has been an individually scheduled Schedule 4 prescription-only medicine since 2018, with its own entry in the Poisons Standard cross-referenced to “MK-677” and “Nutrobal.” Sport Integrity Australia describes it bluntly as “technically a poison” with no toxicity data, and confirms that a therapeutic use exemption would not be granted to athletes. Detection is straightforward: a 2026 hair-testing method can identify a single 10 mg dose. For how each country treats compounds like this one, see our peptide-legality guides for the US, UK and Australia.

The bottom line: MK-677 is unapproved everywhere, prescription-only in Australia since 2018, and banned in sport by WADA.

MK-677’s most frequent documented side effects are increased appetite, lower-extremity oedema (ankle and leg swelling), and mild muscle pain. More concerning are its metabolic effects: multiple trials show raised fasting glucose, reduced insulin sensitivity and increased HbA1c, which is why it is a poor choice for anyone with diabetes, prediabetes or insulin resistance. These effects mirror the metabolic downsides of chronically elevated growth hormone.

The heart-failure signal

The standout safety concern is the congestive-heart-failure signal that stopped the Adunsky hip-fracture trial early, where heart failure occurred in 6.5% of the MK-677 group versus 1.7% on placebo. The FDA cites this risk directly. While that signal arose in an older, frailer population, the absence of long-term safety data in healthy users means the risk in younger people simply has not been characterised. Long-term safety in healthy adults is, in plain terms, unknown.

Product-quality risk

Because MK-677 is sold only through unregulated channels, buyers face the added hazard of product quality. Independent analyses have found mislabelled, misdosed and contaminated products across the grey-market growth-hormone-secretagogue supply, and users on community forums report receiving counterfeit product whose effects vanish after a supplier change. The compound itself is one risk; the unverified vial is another. Our certificate of analysis guide covers how a legitimate third-party test report should read.

The bottom line: MK-677 raises blood glucose, reduces insulin sensitivity, causes fluid retention, and carries a documented congestive-heart-failure signal.

MK-677 is frequently compared with injectable peptides because it promises similar growth-hormone elevation without needles. The trade-offs are worth understanding.

• Versus ipamorelin: both hit the ghrelin receptor, but ipamorelin is a selective injectable peptide designed to spare appetite, cortisol and prolactin, while MK-677 is oral and produces the broader ghrelin response. The full head-to-head lives in our ipamorelin vs MK-677 comparison.
• Versus tesamorelin: tesamorelin is an FDA-approved GHRH analogue with Phase 3 evidence, whereas MK-677 has never been approved. They represent opposite ends of the regulatory spectrum within the same broad class.
• MK-677 is not a SARM and not an anabolic steroid. It does not bind the androgen receptor and has no direct effect on testosterone, despite often being sold on the same sites.

For the full landscape of how oral secretagogues, GHRH analogues and GH-releasing peptides relate, see our growth hormone secretagogues overview.

Is MK-677 a peptide?

No. MK-677 is a non-peptide small molecule, a ghrelin-receptor agonist, that is chemically closer to a conventional drug than to a peptide. It is grouped with peptides for historical and marketing reasons, but it contains no amino-acid chain.

Is MK-677 FDA approved?

No. MK-677 has never been approved for human use in any country. Merck investigated it for several conditions and discontinued development, and it is currently sold only as an unregulated research chemical.

Does MK-677 build muscle?

In a two-year trial in healthy older adults, MK-677 increased fat-free mass but did not improve strength or physical function, and some of the gain is attributed to fluid retention. The reliable IGF-1 rise it produces does not translate into the functional gains often claimed.

Is MK-677 safe?

Documented effects include raised blood glucose, reduced insulin sensitivity, fluid retention and muscle pain, and a hip-fracture trial was halted early over a congestive-heart-failure signal. Long-term safety in healthy users is unknown, and unregulated product adds quality risk.

Is MK-677 legal?

It is not an approved drug anywhere. In Australia it is a Schedule 4 prescription-only medicine, in the UK an unlicensed medicine that cannot be sold for human use, and it is banned in sport at all times by WADA under section S2.2.4.

Is MK-677 being developed as a real medicine?

Yes. As LUM-201, Lumos Pharma is running a Phase 3 trial of ibutamoren in children with growth hormone deficiency, using a predictive enrichment marker to select likely responders. Both the FDA and the European Commission granted it orphan drug designation in 2017.